Review Article Open Access
Volume 2 | Issue 3 | DOI: https://doi.org/10.33696/cancerimmunol.2.021

Methylation Status of Tumor Suppressor Genes in Circulating DNA of PDAC Patients: Facts and Hopes

  • 1Deparment of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi, India
+ Affiliations - Affiliations

Corresponding Author

Anoop Saraya, asaraya@yahoo.com

Received Date: May 30, 2020

Accepted Date: June 28, 2020


Pancreatic cancer is a very aggressive disease with high mortality rate and its high mortality rate makes its diagnosis difficult, especially when disease is at an advanced stage. Lack of efficient biomarkers until today makes its diagnosis difficult at early stages and during its progression. Methylation in the promoter of circulatory DNA, cirDNA of tumor suppressive genes is one of the important epigenetic phenomenon contributes to the pathogenesis of diseases and also opening a new venue for the discovery of non-invasive biomarkers. CirDNA methylation signatures represented an important paradigm shift in precision medicine and enabling early detection and monitoring the progression of pancreatic diseases. In this review we will provide an overview of differential methylation levels in PDAC with diagnostic and prognostic potential at the early stages of diseases.


Pancreatic cancer, Circulatory DNA, Non-invasive biomarker, Epigenetic signature, Diagnosis, Prognosis

Author Information X